Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Thromboprophylactic Treatment with Rivaroxiban or Dabigatran Compared with Enoxaparin or Dalteparin in Patients Undergoing Elective Hip or Knee Replacement Surgery [Internet].

Ringerike T, Hamidi V, Hagen G, Reikvam Å, Klemp M.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2011 Jun.

2.
3.

How to use an article reporting a multiple treatment comparison meta-analysis.

Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH.

JAMA. 2012 Sep 26;308(12):1246-53.

PMID:
23011714
4.

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.

Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E.

BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675. Review.

5.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
6.

American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty.

Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, Yates AC Jr, Boggio LN, Watters WC 3rd, Turkelson CM, Wies JL, Sluka P, Hitchcock K.

J Bone Joint Surg Am. 2012 Apr 18;94(8):746-7. doi: 10.2106/JBJS.9408.ebo746. No abstract available.

7.

Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

Nieto JA, Espada NG, Merino RG, González TC.

Thromb Res. 2012 Aug;130(2):183-91. doi: 10.1016/j.thromres.2012.02.011. Epub 2012 Mar 15.

PMID:
22425218
8.

Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis.

Neumann I, Rada G, Claro JC, Carrasco-Labra A, Thorlund K, Akl EA, Bates SM, Guyatt GH.

Ann Intern Med. 2012 May 15;156(10):710-9. doi: 10.7326/0003-4819-156-10-201205150-00421. Epub 2012 Mar 12. Review.

PMID:
22412038
9.

The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.

Cohen A, Drost P, Marchant N, Mitchell S, Orme M, Rublee D, Simon TA, Sutton A.

Clin Appl Thromb Hemost. 2012 Nov;18(6):611-27. doi: 10.1177/1076029612437579. Epub 2012 Mar 2. Review.

PMID:
22387582
11.

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR.

J Bone Joint Surg Br. 2012 Feb;94(2):257-64. doi: 10.1302/0301-620X.94B2.27850.

PMID:
22323697
12.

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr.

Chest. 2012 Feb;141(2 Suppl):e278S-e325S. doi: 10.1378/chest.11-2404.

13.

Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens.

Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG, Ma Y, Roberts T, Sharrock N, Salvati E.

J Bone Joint Surg Br. 2012 Jan;94(1):113-21. doi: 10.1302/0301-620X.94B1.27301.

PMID:
22219258
14.

Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty.

Mont MA, Jacobs JJ, Boggio LN, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, Yates AJ Jr, Watters WC 3rd, Turkelson CM, Wies JL, Donnelly P, Patel N, Sluka P; AAOS.

J Am Acad Orthop Surg. 2011 Dec;19(12):768-76.

PMID:
22134209
15.

Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.

Alves C, Batel-Marques F, Macedo AF.

J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):266-76. doi: 10.1177/1074248411427402. Epub 2011 Dec 1.

PMID:
22134134
16.

Edoxaban for the prevention of thromboembolic events after surgery.

Gras J.

Drugs Today (Barc). 2011 Oct;47(10):753-61. doi: 10.1358/dot.2011.47.10.1709241. Review.

PMID:
22076490
17.

Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.

Friedman RJ.

Orthopedics. 2011 Oct;34(10):795-804. doi: 10.3928/01477447-20110826-24. Review.

PMID:
21956181
18.

The role of apixaban for venous and arterial thromboembolic disease.

Prom R, Spinler SA.

Ann Pharmacother. 2011 Oct;45(10):1262-83. doi: 10.1345/aph.1Q119. Epub 2011 Sep 27. Review.

PMID:
21954450
19.

GRADE guidelines 6. Rating the quality of evidence--imprecision.

Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW Jr, Murad MH, Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ.

J Clin Epidemiol. 2011 Dec;64(12):1283-93. doi: 10.1016/j.jclinepi.2011.01.012. Epub 2011 Aug 11.

PMID:
21839614
20.

Supplemental Content

Support Center